Demographic disparities were observed in survival trends of patients with esophageal squamous cell carcinoma, with male sex and non-Hispanic Black race associated ... researchers analyzed data from ...

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

Workers at the time didn’t realize it was dangerous. Lung cancer caused by asbestos has the same symptoms, treatment options, and prognosis as other forms of lung cancer. The only difference is that ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

9, 2025 — Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of ... well-known role in signaling at the cell surface. Mutant RAS, they ...

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at ...

In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...

LC is the leading cause of cancer death worldwide; poor survival is driven by late onset of non-specific symptoms, resulting in late-stage diagnoses. Evidence for the efficacy of screening in ...

New Screening Device Shows Promise for Early Lung ... Cancer Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal ...

Pulmonary rehabilitation, a program of exercise and education to increase awareness about your lungs and your disease, is a common part of improving lung function in people with lung cancer.

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...